377 related articles for article (PubMed ID: 12721511)
21. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
22. Acromegaly: a new therapy.
Friend KE
Cancer Control; 2002; 9(3):232-5. PubMed ID: 12090246
[TBL] [Abstract][Full Text] [Related]
23. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.
Melmed S; Sternberg R; Cook D; Klibanski A; Chanson P; Bonert V; Vance ML; Rhew D; Kleinberg D; Barkan A
J Clin Endocrinol Metab; 2005 Jul; 90(7):4405-10. PubMed ID: 15827109
[TBL] [Abstract][Full Text] [Related]
24. New formulations and approaches in the medical treatment of acromegaly.
Debono M; Newell-Price J
Curr Opin Endocrinol Diabetes Obes; 2010 Aug; 17(4):350-5. PubMed ID: 20502324
[TBL] [Abstract][Full Text] [Related]
25. Treatment of acromegaly: future.
Donangelo I; Melmed S
Endocrine; 2005 Oct; 28(1):123-8. PubMed ID: 16311419
[TBL] [Abstract][Full Text] [Related]
26. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
Cozzi R; Attanasio R; Lodrini S; Lasio G
Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
[TBL] [Abstract][Full Text] [Related]
27. Current and future medical treatments for patients with acromegaly.
Maffezzoni F; Formenti AM; Mazziotti G; Frara S; Giustina A
Expert Opin Pharmacother; 2016 Aug; 17(12):1631-42. PubMed ID: 27352098
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of pituitary adenomas].
Mezosi E; Nemes O
Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
[TBL] [Abstract][Full Text] [Related]
29. Current management of acromegaly.
Díez JJ; Iglesias P
Expert Opin Pharmacother; 2000 Jul; 1(5):991-1006. PubMed ID: 11249504
[TBL] [Abstract][Full Text] [Related]
30. Treatment of pituitary tumors: somatostatin.
Tichomirowa MA; Daly AF; Beckers A
Endocrine; 2005 Oct; 28(1):93-100. PubMed ID: 16311415
[TBL] [Abstract][Full Text] [Related]
31. Therapy for the syndromes of GH excess.
Arosio M; Cannavò S; Epaminonda P; Ronchi C; Chiodini I; Adda G
J Endocrinol Invest; 2003; 26(10 Suppl):36-43. PubMed ID: 15497658
[TBL] [Abstract][Full Text] [Related]
32. Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs.
Chanson P
Neuroendocrinology; 2016; 103(1):50-8. PubMed ID: 25677539
[TBL] [Abstract][Full Text] [Related]
33. How effective are current therapies for acromegaly?
Freda PU
Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S144-51. PubMed ID: 12914744
[TBL] [Abstract][Full Text] [Related]
34. New medical treatment for acromegaly.
van der Lely AJ; de Herder WW; Lamberts SW
Pituitary; 1999 Jun; 2(1):89-92. PubMed ID: 11081177
[TBL] [Abstract][Full Text] [Related]
35. Current status and future directions of pharmacological therapy for acromegaly.
Mercado M; Espinosa E; Ramírez C
Minerva Endocrinol; 2016 Sep; 41(3):351-65. PubMed ID: 26485036
[TBL] [Abstract][Full Text] [Related]
36. Optimizing somatostatin analog therapy in acromegaly: long-acting formulations.
Gilroy JJ; James RA
Treat Endocrinol; 2002; 1(3):149-54. PubMed ID: 15799207
[TBL] [Abstract][Full Text] [Related]
37. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R
J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and limits of somatostatin analogs.
Petersenn S
J Endocrinol Invest; 2005; 28(11 Suppl International):53-7. PubMed ID: 16625846
[TBL] [Abstract][Full Text] [Related]
39. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly.
Neggers SJ; van Aken MO; Janssen JA; Feelders RA; de Herder WW; van der Lely AJ
J Clin Endocrinol Metab; 2007 Dec; 92(12):4598-601. PubMed ID: 17895318
[TBL] [Abstract][Full Text] [Related]
40. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm.
Clemmons DR; Chihara K; Freda PU; Ho KK; Klibanski A; Melmed S; Shalet SM; Strasburger CJ; Trainer PJ; Thorner MO
J Clin Endocrinol Metab; 2003 Oct; 88(10):4759-67. PubMed ID: 14557452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
